297 related articles for article (PubMed ID: 12877888)
21. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
22. [Heparin concentration and hemostatic alterations with low systemic heparinization during CPB using heparin-coated circuits].
Yoshie M; Hirose Y; Gamo M; Matsuo K
Masui; 2001 Feb; 50(2):179-83. PubMed ID: 11244775
[TBL] [Abstract][Full Text] [Related]
23. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
24. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
25. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system.
Jensen E; Andréasson S; Bengtsson A; Berggren H; Ekroth R; Larsson LE; Ouchterlony J
Ann Thorac Surg; 2004 Mar; 77(3):962-7. PubMed ID: 14992907
[TBL] [Abstract][Full Text] [Related]
26. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).
Hazama S; Eishi K; Yamachika S; Noguchi M; Ariyoshi T; Takai H; Odate T; Matsukuma S; Onohara D; Yanatori M
Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):90-6. PubMed ID: 15209550
[TBL] [Abstract][Full Text] [Related]
28. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
30. Comparison of minimally invasive closed circuit extracorporeal circulation with conventional cardiopulmonary bypass and with off-pump technique in CABG patients: selected parameters of coagulation and inflammatory system.
Wippermann J; Albes JM; Hartrumpf M; Kaluza M; Vollandt R; Bruhin R; Wahlers T
Eur J Cardiothorac Surg; 2005 Jul; 28(1):127-32. PubMed ID: 15939621
[TBL] [Abstract][Full Text] [Related]
31. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(6):275-81. PubMed ID: 9498931
[TBL] [Abstract][Full Text] [Related]
32. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
[TBL] [Abstract][Full Text] [Related]
33. Biocompatibility of poly2methoxyethylacrylate coating for cardiopulmonary bypass.
Noguchi M; Eishi K; Tada S; Yamachika S; Hazama S; Izumi K; Tanigawa K
Ann Thorac Cardiovasc Surg; 2003 Feb; 9(1):22-8. PubMed ID: 12667126
[TBL] [Abstract][Full Text] [Related]
34. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
Dietrich W
J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
[TBL] [Abstract][Full Text] [Related]
35. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
36. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
[TBL] [Abstract][Full Text] [Related]
37. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
[TBL] [Abstract][Full Text] [Related]
38. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
[TBL] [Abstract][Full Text] [Related]
39. The use of minimized extracorporeal circulation system has a beneficial effect on hemostasis--a randomized clinical study.
Abdel-Rahman U; Martens S; Risteski P; Ozaslan F; Riaz M; Moritz A; Wimmer-Greinecker G
Heart Surg Forum; 2006; 9(1):E543-8. PubMed ID: 16403712
[TBL] [Abstract][Full Text] [Related]
40. [Increased fibrinolytic activity during surgery with cardiopulmonary bypass].
Gando S; Tedo I; Goda Y; Kubota M
Masui; 1990 Jun; 39(6):751-6. PubMed ID: 2388394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
